Johnson & Johnson (JNJ) Receives Conditional Marketing Authorization from EMA for 'Tecvayli' as a Treatment for Multiple Myeloma
First BCMA Bispecific Antibody Approved in the European Market
Johnson & Johnson's (JNJ) multiple myeloma treatment, Tecvayli (teclistamab), received conditional marketing authorization from the European Medicines Agency (EMA) on August 23, 2022. This marks the first approval in Europe for a bispecific antibody therapy that simultaneously targets B-cell maturation antigen (BCMA) and the CD3 receptor on T cells. Tecvayli is approved for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies. This approval is expected to significantly benefit patients with extremely poor prognoses who have failed all standard treatments, offering a completely new immunotherapy option.
Demonstrated High Efficacy Based on the MajesTEC-1 Clinical Trial
The regulatory approval is based on the Phase 1/2 MajesTEC-1 trial, which demonstrated excellent clinical efficacy for Tecvayli. In a heavily pre-treated patient population, Tecvayli achieved an objective response rate (ORR) of 63.0% and a median progression-free survival (mPFS) of 11.4 months, demonstrating deep and durable efficacy. Notably, 46.1% of responders achieved a complete response (CR) or better, and the median duration of response (mDOR) was 24.0 months. This suggests that Tecvayli, compared to cell therapies (CAR-T), can be administered immediately (off-the-shelf), potentially addressing the significant unmet needs of patients with rapidly progressing relapsed multiple myeloma.
Shifting Landscape in the Multiple Myeloma Market and Intense Competition
The global multiple myeloma treatment market is currently a major oncology area, with an estimated value of USD 25 billion to USD 31 billion by 2026. Tecvayli has gained a first-mover advantage in this large market by receiving conditional marketing authorization from the EMA before its competitor, Pfizer's (PFE) Elrexfio (elranatamab). Elrexfio received conditional approval from the EMA in December 2023, giving Tecvayli a one-year head start in market establishment. Janssen is further solidifying its market dominance with a strong multiple myeloma portfolio, including the established blockbuster therapy Darzalex (daratumumab), Tecvayli, and talquetamab.
Transition from Conditional Approval to Full Commercialization
The EMA's conditional marketing authorization requires the submission of confirmatory clinical data in the future, but it plays a crucial role in providing patients with access to innovative therapies quickly. Tecvayli has already received accelerated approval from the U.S. Food and Drug Administration (FDA) in October 2022 and is preparing for expansion into earlier lines of therapy through ongoing clinical trials, including MajesTEC-3 and MajesTEC-9. In the future, negotiations with European national health authorities regarding pricing and reimbursement will be key determinants of Tecvayli's initial sales growth. As it was developed through a collaboration with Genmab (GMAB) using the DuoBody technology platform, commercial sales will also accelerate milestone payments and royalties to its partners.
The EMA's conditional approval of Tecvayli represents a significant milestone, demonstrating that an off-the-shelf bispecific antibody therapy, which is an alternative to the complex manufacturing requirements of CAR-T therapies, has successfully reached the commercialization stage. In the short term, it provides a strong commercial advantage by securing a one-year lead in the European market over Pfizer's Elrexfio, allowing for maximized early market share. In the medium to long term, it creates momentum for accelerating entry into the second-line treatment setting through combination studies with existing Janssen portfolio products, such as Darzalex, as the global multiple myeloma market expands to approximately USD 30 billion. Furthermore, the royalty agreement with Genmab (GMAB), which provides the bispecific antibody technology, is expected to positively impact stock price and pipeline valuation through diversified cash flow generated by sales growth.
Source: EMA (ema)